GenSight Biologics S.A. (EPA:SIGHT)
France flag France · Delayed Price · Currency is EUR
0.0789
-0.0039 (-4.71%)
At close: Jan 30, 2026

GenSight Biologics Income Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Revenue
0.191.51.272.585.284.39
Other Revenue
0.751.131.72.282.433.05
0.952.632.964.877.717.44
Revenue Growth (YoY)
-52.18%-11.44%-39.07%-36.89%3.62%51.53%
Gross Profit
0.952.632.964.877.717.44
Selling, General & Admin
5.786.0713.313.3612.929.99
Research & Development
10.3712.3719.3619.3422.9222.39
Operating Expenses
16.1518.4432.6632.735.8432.37
Operating Income
-15.2-15.81-29.7-27.84-28.13-24.93
Interest Expense
-0.09-1.55-3.15-2.65-2.17-1.72
Currency Exchange Gain (Loss)
-0.160.19-0.210.650.37-0.09
Other Non Operating Income (Expenses)
0.343.26.842.211.31-7.27
EBT Excluding Unusual Items
-15.11-13.98-26.22-27.62-28.62-34.01
Pretax Income
-15.11-13.98-26.22-27.62-28.62-34.01
Income Tax Expense
0.010.02-0.0100
Net Income
-15.12-14-26.22-27.63-28.62-34.02
Net Income to Common
-15.12-14-26.22-27.63-28.62-34.02
Shares Outstanding (Basic)
1199648464535
Shares Outstanding (Diluted)
1199648464535
Shares Change (YoY)
77.81%98.18%4.29%2.61%28.54%23.76%
EPS (Basic)
-0.13-0.15-0.54-0.60-0.63-0.97
EPS (Diluted)
-0.13-0.15-0.54-0.60-0.63-0.97
Free Cash Flow
-8.05-12.94-24.67-34.01-17.17-15.05
Free Cash Flow Per Share
-0.07-0.14-0.51-0.73-0.38-0.43
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-1608.57%-602.44%-1001.86%-572.15%-364.86%-335.13%
Profit Margin
-1600.00%-533.37%-884.62%-567.83%-371.21%-457.19%
Free Cash Flow Margin
-851.96%-492.88%-832.42%-698.97%-222.74%-202.28%
EBITDA
-15.53-15.65-27.52-26.77-27.2-24.01
D&A For EBITDA
-0.330.162.181.060.930.93
EBIT
-15.2-15.81-29.7-27.84-28.13-24.93
Revenue as Reported
0.942.632.964.877.717.44
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.